The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...
Traditional deep brain stimulation surgery can take up to 10 hours to complete, with the patient wide awake. This robotic ...
The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.In a press release, Supernus ...
The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...
Three strikes and you’re out? Not for Supernus and its Parkinson’s disease infusion pump. | The device is meant to allow ...
Richard Balanson says when one suffers a disease "you begin to accumulate friends" who have their own story with the same ...
The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...
In a new study, participants who exercised 150 minutes per week—whether on one or two days, or more consistently—saw a host ...
Mike Forrester with AP Former East Oregonian editor Mike Forrester, right, is pictured here in his early news career as a reporter for the Associated Press in Los Angeles with world heavyweight boxing ...
The singer-songwriter gained recognition from the Recording Academy in the early 1990s, winning the Grammy for Best New ...
The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...
Supernus Pharmaceuticals has won Food and Drug Administration approval for its Onapgo device to treat patients with Parkinson's disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback